Karine Lebras-Celli
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Multicenter Flow Cytometry For Acute Myeloid Leukemia Measurable Residual Disease With LAIP/DfN And CD34+CD38- Leukemic Stem Cell-Enriched Populations.
Journal: Journal of visualized experiments : JoVE
Published: August 10, 2026
Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.
Journal: Leukemia
Published: April 14, 2026
Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.
Journal: Blood cancer journal
Published: March 11, 2026
Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.
Journal: Blood cancer journal
Published: March 10, 2026
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.
Journal: Leukemia
Published: August 25, 2025
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Journal: NEJM evidence
Published: June 24, 2025
Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic Profiles.
Journal: European journal of haematology
Published: March 27, 2025
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Journal: Blood cancer journal
Published: April 03, 2024
Last Updated: 09/26/2026